ALK and clear cell sarcoma: Following this observation, the drug was also reported to be active in ALK-positive IMT [48], MET-positive alveolar soft part sarcoma [49], and MET-positive clear-cell sarcoma [50], in the biomarker-driven phase 2 EORTC 90101 CREATE trial.